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Abstract
Background: North American pediatric rheumatologists have created an investigator-initiated
research network (the Childhood Arthritis and Rheumatology Research Alliance – CARRA) to
facilitate multi-centre studies. One of the first projects undertaken by this network was to define,
by consensus, research priorities for the group, and if possible a first group-sponsored clinical trial
in which all members could participate.
Methods: We determined consensus using the Delphi approach. This approach has been used
extensively in health research to reach consensus in large groups. It uses several successive
iterations of surveys eliciting ideas and opinions from specialists in the field. Three surveys were
designed based on this method and were distributed to members of CARRA to elicit and rank-
order research priorities.
Results: A response rate of 87.6% was achieved in the final survey. The most highly ranked
research suggestion was to study infliximab treatment of uveitis unresponsive to methotrexate.
Other highly ranked suggestions were to study i) the treatment of systemic arthritis with anakinra
and ii) the treatment of pediatric systemic lupus erythematosus with mycophenolate mofetil.
Conclusion: The Delphi approach was an effective and practical method to define research
priorities in this group. Ongoing discussion and cooperation among pediatric rheumatologists in
CARRA and others world-wide will help in developing further research priorities and to facilitate
the execution of clinical trials in the future.
Background
The rare nature of pediatric rheumatology conditions
poses challenges in conducting adequately powered trials
in single institutions. Recognizing the need for – and the
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previous successes of – multicentre collaborations, the
Childhood Arthritis and Rheumatology Research Alliance
(CARRA) was formed in 2002 as an investigator-initiated
research network aiming to improve outcomes of children
with pediatric rheumatic diseases through high-quality
clinical trials and clinical translational research. [1]
As a starting point, a CARRA sub-committee surveyed
CARRA members to identify and prioritize research ques-
tions. The goal of this project was to identify research pri-
orities for an intervention study addressing a pediatric
rheumatology problem that is sufficiently common that
centres across the network would have an opportunity to
participate, but one that is sufficiently rare that the work-
load at each institution would not be excessive.
Our chosen consensus method was the Delphi approach
[2] which has been applied extensively to develop
research priorities in social work [3], acute care [4], infec-
tion control and hospital epidemiology [5], health serv-
ices [6], surgical infection [7], and nursing. [8] This
method achieves consensus in a large group setting using
successive iterations of questionnaires with controlled
feedback. The first questionnaire asks individuals to
respond to a broad question. Each subsequent question-
naire is developed based on the responses from the pre-
ceding questionnaire and the process is repeated until
consensus has been reached or when sufficient informa-
tion exchange is obtained. [9] This approach offers many
benefits. The participants are not required to meet as a
group, enabling responses to be submitted from individu-
als who are far apart geographically. [2] The lack of face-
to-face contact ensures participant anonymity which
reduces peer pressure that can occur in consensus confer-
ences [2,9].  The Delphi approach also balances the effect
of dominant personality types in the determination of the
final consensus. [2,9]
The Delphi approach has been widely used in the pediat-
ric rheumatology field, both alone and in combination
with the Nominal Group Technique; a structured group-
meeting format where meeting participants generate, clar-
ify, and methodically vote for ideas until achieving con-
sensus. [9] These processes have yielded criteria for
clinical remission in some categories of juvenile idio-
pathic arthritis [10], core sets of measures for disease
activity and damage in juvenile dermatomyositis and
juvenile systemic lupus erythematosus [11], definitions of
improvement in juvenile [12] and adult rheumatoid [13]
arthritis, definitions of improvement in adult and juvenile
myositis, [14] and to develop guidelines for trials of ther-
apies in idiopathic inflammatory myopathies. [15]
The specific aim of this study was to determine pediatric
rheumatology research priorities for CARRA using the
Delphi technique.
Methods
The study was carried out between October 2003 and June
2004.
Study population
Our participants were members of the Childhood Arthri-
tis and Rheumatology Research Alliance (CARRA), repre-
senting pediatric rheumatology experts across Canada and
the United States.
Questionnaires
The Delphi approach is a systematic process used to gen-
erate ideas and arrive at consensus in a large group. The
first step in our study involved soliciting research ideas
using an open-ended questionnaire. These research sug-
gestions were collated and categorized, and a second
questionnaire was created with the intent of identifying
the most widely accepted suggestions. The most highly
endorsed research ideas were sent out in a third question-
naire, to be priority-ranked by the participants (See Figure
1).
First questionnaire
The first questionnaire used an open-ended format with
two questions: "What disease or problem should be studied in
the first protocol"? and "What treatment should be studied for
this disease?". The questionnaire specified that the pro-
posed study should be a single-arm treatment study of a
rare disease or uncommon manifestation of disease, for
which a randomized trial would not likely be feasible at
the current time. The treatment should be one of interest
to the group but not overly controversial so that the
majority of CARRA members would feel comfortable
enrolling subjects.
Respondents were asked to be as specific as possible and
to provide a rationale or justification for their disease of
choice and for the recommendation of the therapeutic
approach for the study. Participants could respond via
email, fax, or postal mail.
Second questionnaire
Responses from the first survey were compiled and tallied.
Participants were sent a list of suggestions in a new ques-
tionnaire and were asked to check off their top ten choices
indicating what they would like to see studied across
CARRA. They were asked to respond based on the feasibil-
ity as a single-arm CARRA supported study, the impor-
tance of the research question, and the availability of
treatments. Only suggestions for single-arm clinical trials
were included.Pediatric Rheumatology 2008, 6:5 http://www.ped-rheum.com/content/6/1/5
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Third questionnaire
In the final questionnaire, the top eight suggestions – 8
were chosen rather than more or fewer based on a natural
cut-off in the rankings – from the single-arm clinical trial
list were sent to all members, along with a count of the
number of top-ten votes that each garnered and the origi-
nal rationale for the study. Respondents were asked to
rank-order each option (with no ties) based on the same
criteria as the second questionnaire (feasibility, impor-
tance, and availability of treatments). Systemic-onset
juvenile rheumatoid arthritis treated with anti-IL-6 recep-
tor antibody was a popular choice in the second question-
naire but the drug would not be available for study in the
near future in North America so it was not a viable option
for the project and was omitted along with an explanation
on the covering letter.
Survey methods
The Tailored Design Method [16], a method that maxi-
mizes the response rate of mail and internet surveys, was
Delphi approach for establishing pediatric rheumatology research priorities Figure 1
Delphi approach for establishing pediatric rheumatology research priorities.Pediatric Rheumatology 2008, 6:5 http://www.ped-rheum.com/content/6/1/5
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used. All correspondence was conducted using electronic
mail, including a "pre-notice", that alerted respondents to
the forthcoming questionnaire. An initial mail-out was
sent soon thereafter with attachments. Approximately 10
days later a reminder email was sent to those who had not
responded. Two subsequent reminders were sent approx-
imately 10 days apart. One and a half months after the
first mail-out, the research coordinator made follow-up
phone calls to all who had not responded after the
reminder emails.
Analysis
No analysis was needed for the first phase; all suggestions
were included. Responses were grouped into disease cate-
gories for the subsequent questionnaire.
For the second step, all survey responses were double
entered into a specially prepared database to ensure key-
ing accuracy. Top-rated suggestions were determined
based on natural cut-offs.
For the last questionnaire iteration, all responses were
double entered into a computer database. Median rank-
ings and 95% confidence intervals were calculated for
each of the eight research suggestions. The Kruskal-Wallis
nonparametric analysis of variance was used to compare
responses to determine whether the most highly ranked
suggestion was indeed statistically significantly different
from other suggestions. Statistical calculations used Data-
Desk 6.2.1 software (Data Description Inc., Ithaca, NY).
Results
All 107 CARRA members at the time of the study were
contacted to participate in the surveys. One member was
removed from our mailing list because the e-mail address
was not functional and repeated attempts to contact the
member were unsuccessful. One other member no longer
worked at the institution listed in the CARRA directory
and no forwarding address was given. Despite attempts to
locate this person, no contact information was found and
this person was also removed from the mailing list.
Iteration 1
Eighty-one out of 105 eligible pediatric rheumatologists
(77.1%) responded to the first questionnaire. Many sug-
gestions were made and there were many duplicates. (All
suggestions are in Appendix A. See additional file 1:
Appendix A: Verbatim Responses for First Delphi Ques-
tionnaire). Twenty-four respondents did not submit any
suggestions.
Iteration 2
Eighty-six out of 105 pediatric rheumatologists (81.9%)
responded to the second questionnaire. The most highly-
endorsed suggestion was to study systemic-onset juvenile
rheumatoid arthritis (JRA) treated with anti-IL 6 (62 votes),
followed by uveitis (JRA, sarcoid, or idiopathic) unresponsive
to methotrexate treated with infliximab (50 votes), pediatric
systemic lupus erythematosus (SLE) treated with mycopheno-
late mofetil (48 votes), and thrombocytopenia unresponsive to
standard therapy in SLE treated with rituximab (47 votes). A
full list of suggested problems and treatments and their
number of votes are in Table 1.
Iteration 3
Ninety-two out of 105 eligible pediatric rheumatologists
(87.6%) responded to the third questionnaire. The most
highly ranked item was uveitis (JRA, sarcoid, or idiopathic)
unresponsive to methotrexate treated with infliximab, with a
mean ranking score of 2.86 and median ranking of 2 (con-
fidence limits 1, 3 a = 0.05). This item was significantly
different from all other items (T = 175.85, p < 0.0001). A
complete list of rankings is in Table 2.
Discussion
CARRA is a network of pediatric rheumatologists that was
formed to answer top-priority questions with potential to
improve the care of children with rheumatic diseases. [1]
Soon after its establishment, this group surveyed its mem-
bers to define its research priorities and identified uveitis
(JRA, sarcoid, or idiopathic) unresponsive to methotrexate
treated with infliximab as the top priority for a single-arm
treatment trial in this research network. Other top-priority
single-arm trials included systemic onset JRA treated with
anakinra  and  pediatric SLE treated with mycophenolate
mofetil. The Delphi approach was a feasible and successful
method to identify these research priorities.
To our knowledge, this is the first study of its kind in this
subspecialty. Most published literature on pediatric rheu-
matology priorities focus on enhancing residency pro-
grams and the need for expansion of the subspecialty [17-
20]. The Pediatric Rheumatology International Trials
Organization (PRINTO) has not surveyed its members to
determine research priorities on an international level
(personal communication, January 16, 2007), and to our
knowledge there have been no initiatives in other coun-
tries or regions to establish such priorities. A survey of
pediatric rheumatologists in North America and Europe
was performed to determine types of ongoing trials in the
field, to identify any problems encountered in these trials,
and willingness to participate in collaborative studies but
did not identify actual research topics or priorities[21].
We surveyed all CARRA members and achieved a high
response rate; however there are a substantial number of
pediatric rheumatologists that are not affiliated with
CARRA and are therefore not represented in our study. As
it is a North American network, the opinions of those who
practice or do research in other continents are also notPediatric Rheumatology 2008, 6:5 http://www.ped-rheum.com/content/6/1/5
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included. Pediatric rheumatology research priorities in
North America may differ substantially from those in
Europe or the developing world due to differences in
availability of medications, access to health care, referral
patterns, and cultural acceptability of treatment, and thus
our survey results represent only the opinions of a subset
of North American pediatric rheumatologists.
CARRA is a large organization that, at the time of our sur-
vey had 107 members and has now grown to 171 mem-
bers. Members are typically interested in research and
represent a sizable proportion of pediatric rheumatolo-
gists in North America. There were 34 physicians taking
care of children with rheumatic diseases in Canada in the
year this survey was conducted (personal communication,
August 8, 2007) of which nine were CARRA members;
and there were an estimated 192 to 215 board certified
pediatric rheumatologists in the United States (personal
communication, American Board of Pediatrics, August 8,
2007) of which 92 were contacted for this survey. Over
40% of those treating children with rheumatic diseases
were therefore represented in our survey. Six additional
CARRA members are sponsored members with PhD
degrees with expertise in pediatric rheumatology. With
Table 1: Delphi 2 Responses in order of descending number of votes
PROBLEM TREATMENT VOTES
Systemic onset juvenile rheumatoid arthritis Anti-IL-6 receptor antibody 62
Uveitis (juvenile rheumatoid arthritis, sarcoid, or idiopathic) 
unresponsive to methotrexate
Infliximab 50
Pediatric systemic lupus erythematosus Mycophenolate mofetil 48
Thrombocytopenia unresponsive to standard therapy in systemic 
lupus erythematosus
Rituximab 47
Juvenile dermatomyositis unresponsive to prednisone and disease-
modifying anti-rheumatic drugs
Enbrel 43
Systemic onset juvenile rheumatoid arthritis Thalidomide 43
Systemic onset juvenile rheumatoid arthritis Anakinra 36
Localized scleroderma Combination: steroids and methotrexate 35
Juvenile dermatomyositis unresponsive to prednisone and disease-
modifying anti-rheumatic drugs
Infliximab 29
Rash of juvenile dermatomyositis Topical tacrolimus 27
Systemic lupus erythematosus proliferative nephritis unresponsive 
to pulse cyclophosphamide and mycophenolate mofetil
Combination: pulse cyclophosphamide and mycophenolate mofetil 25
Chronic Recurrent Multifocal Osteomyelitis that is not controlled 
by non-steroid anti-inflammatory drugs and/or that requires 
corticosteroids
Bisphosphonates 24
Localized scleroderma Methotrexate orally 20
Linear scleroderma refractory to oral or subcutaneous 
methotrexate treatment
Oral mycophenolate mofetil treatment 19
Henoch Scholein Purpura Glucocorticoid treatment 18
Osteoporosis Alendronate and other possibilities 18
Pauciarticular juvenile rheumatoid arthritis Intraarticular steroids 17
Systemic onset juvenile rheumatoid arthritis Combination:TNF blockers and thalidomide 17
Behcet's Infliximab 16
Early polyarticular juvenile rheumatoid arthritis CTLA4-1g 16
Macrophage activation syndrome Combination: cyclosporin + corticosteroids 15
Sarcoid arthritis Enbrel 15
Severe systemic lupus erythematosus – cyclophosphamide 
dependent or resistant
Intravenous fludarabine 15
Rash of systemic lupus erythematosus Topical tacrolimus 14
Acute rheumatic fever Naproxen 13
Henoch Scholein Purpura with abdominal pain Glucocorticoid treatment 13
Juvenile rheumatoid arthritis-temporomandibular joint arthritis Corticosteroid joint injections 13
Systemic onset juvenile rheumatoid arthritis Oral intravenous immunoglobulin as adjuvant therapy 10
Familial Mediterranean fever not responsive to colchicine Anakinra 8
Refractory iritis in juvenile rheumatoid arthritis Cyclosporin 8
Osteoporosis Vitamin D – the various preparations 7
Raynaud's 10 and 20 Biofeedback 7
Familial Mediterranean fever Anti-Interleukin 1 5
Systemic onset juvenile rheumatoid arthritis Combination: hydroxychloroquine and standard therapy 2
Systemic onset juvenile rheumatoid arthritis Combination: thalidomide and cyclosporin 2Pediatric Rheumatology 2008, 6:5 http://www.ped-rheum.com/content/6/1/5
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our high response rate, we are confident that our results
are reasonably representative of those pediatric rheuma-
tologists in North America with research interests.
The process that was undertaken by this group has
resulted in the identification of important research ideas,
with the two most highly-endorsed topics currently mov-
ing forward for scientific investigation. A request-for-pro-
posals was put forth to investigate the top-rated
suggestion of infliximab treatment in patients with per-
sistent uveitis, and a CARRA-funded study is currently
underway. A proposal for investigating the treatment
effect of IL-1 inhibition in patients with systemic-onset
juvenile arthritis has also been developed by CARRA
investigators and has secured funding.
Conclusion
In summary, the Delphi method was successfully used to
identify pediatric rheumatology research priorities in
North America. The top-priority for a single-arm trial was
identified as a study for uveitis patients (JRA, sarcoid, or
idiopathic) unresponsive to methotrexate, treated with
infliximab. This provides a starting point for further
research and clinical trials in pediatric rheumatology.
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